Researchers were so encouraged by early results from a study on preventing breast cancer recurrence that they halted their work so more women can benefit from the findings.
The study, published online Thursday by the New England Journal of Medicine, showed breast cancer patients who follow up five years of tamoxifen treatment with letrozole, an estrogen suppressor, cut the risk of recurrence by nearly half.
Doctors involved in the study said the findings could benefit hundreds of thousands of women uncertain about what to do after taking tamoxifen, which loses much of its effectiveness after five years. The drug is the top hormonal treatment for estrogen-fueled tumors.
"The result has provided women with hope," said Kathy Anderson, a breast cancer survivor who took part in the study.
The study involved more than 5,000 women in North America and Europe with the most common form of breast cancer who had completed the recommended five years of tamoxifen treatment.
They were given either letrozole or a dummy pill, and results showed that within an average of 2.4 years, 207 had a cancer recurrence -- 75 of those on letrozole and 132 of those taking the placebo.
Because of those results, the research was halted so those participants getting the placebo could begin taking letrozole. Publication of the results, which will appear in the journal's Nov. 6 issue, was moved up because of the importance of the findings.
Letrozole is made by Novartis Pharmaceuticals and sold under the brand name Femara. It paid more than half the cost of conducting the US$15 million study, and also supplied all the letrozole and placebo pills used, officials said.
Doctors who ran the study told a news conference Thursday that the opportunity to help so many women prevailed over the desire for more substantive long-term findings.
"This is available and can provide potentially meaningful reduction in risk of recurrence," said Dr James Ingle, of the Mayo Clinic in Rochester, Minnesota
A journal editorial published alongside the study supported the decision.
"At a minimum, suitable patients must be apprised of these important observations and must be given the opportunity to receive letrozole, with an understanding of the limitations of the data," said the editorial by Dr Norman Wolmark of Allegheny General Hospital in Pittsburgh.
Estrogen fuels the growth of about half of all breast cancers, especially those in older women. Tamoxifen is given to almost all such US patients after surgery to help prevent breast tumors from returning.
Tamoxifen, the top treatment to stall tumor growth, prevents estrogen from linking up to a receptor on the surface of cancer cells.
However, tamoxifen's effectiveness ends after five years, apparently because the body develops a resistance to it, said Dr Paul Goss of Princess Margaret Hospital in Toronto.
He headed the study by 18 doctors from Canadian, European and US hospitals, universities and cancer centers.
Estrogen pushes dormant tumors to grow, he said, so the study looked at what happened if patients took an estrogen inhibitor such as letrozole. Goss and Ingle said further study was required on the effects of prolonged letrozole use.
Side effects include increased risk of osteoporosis, hot flashes, night sweats, and pain in the bones, joints or back. Letrozole costs about US$6 per pill and is taken daily, Ingle said.
Goss said the findings help him go to work "with a lighter step" because he can tell patients that "yes, something is happening."
‘SHORTSIGHTED’: Using aid as leverage is punitive, would not be regarded well among Pacific Island nations and would further open the door for China, an academic said New Zealand has suspended millions of dollars in budget funding to the Cook Islands, it said yesterday, as the relationship between the two constitutionally linked countries continues to deteriorate amid the island group’s deepening ties with China. A spokesperson for New Zealand Minister of Foreign Affairs Winston Peters said in a statement that New Zealand early this month decided to suspend payment of NZ$18.2 million (US$11 million) in core sector support funding for this year and next year as it “relies on a high trust bilateral relationship.” New Zealand and Australia have become increasingly cautious about China’s growing presence in the Pacific
The team behind the long-awaited Vera Rubin Observatory in Chile yesterday published their first images, revealing breathtaking views of star-forming regions as well as distant galaxies. More than two decades in the making, the giant US-funded telescope sits perched at the summit of Cerro Pachon in central Chile, where dark skies and dry air provide ideal conditions for observing the cosmos. One of the debut images is a composite of 678 exposures taken over just seven hours, capturing the Trifid Nebula and the Lagoon Nebula — both several thousand light-years from Earth — glowing in vivid pinks against orange-red backdrops. The new image
ESPIONAGE: The British government’s decision on the proposed embassy hinges on the security of underground data cables, a former diplomat has said A US intervention over China’s proposed new embassy in London has thrown a potential resolution “up in the air,” campaigners have said, amid concerns over the site’s proximity to a sensitive hub of critical communication cables. The furor over a new “super-embassy” on the edge of London’s financial district was reignited last week when the White House said it was “deeply concerned” over potential Chinese access to “the sensitive communications of one of our closest allies.” The Dutch parliament has also raised concerns about Beijing’s ideal location of Royal Mint Court, on the edge of the City of London, which has so
Canada and the EU on Monday signed a defense and security pact as the transatlantic partners seek to better confront Russia, with worries over Washington’s reliability under US President Donald Trump. The deal was announced after a summit in Brussels between Canadian Prime Minister Mark Carney and European Commission President Ursula von der Leyen and European Council President Antonio Costa. “While NATO remains the cornerstone of our collective defense, this partnership will allow us to strengthen our preparedness ... to invest more and to invest smarter,” Costa told a news conference. “It opens new opportunities for companies on both sides of the
RSS